Rapid Response of Palmoplantar Psoriasis to Risankizumab: A Case Report.

Palmoplantar psoriasis, a clinical variant of plaque psoriasis, has a significant impact by causing deterioration in the social and functional aspects of patients' lives. Numerous therapeutic interventions are available for palmoplantar psoriasis. Although emerging biological agents have had an enormous positive impact on chronic plaque psoriasis, studies assessing their effectiveness in the palmoplantar phenotype are limited in the literature. We therefore present a case report of a patient with a 10-year history of palmoplantar psoriasis, which has significantly impacted her occupational life. She was treated with Risankizumab, showing a significant and rapid improvement in her symptoms. We believe that Risankizumab could be one of the most effective therapeutic interventions in the clinical context where rapid clearance of palmoplantar psoriasis is required.

Introduction

Palmoplantar psoriasis is a regional phenotype of plaque psoriasis that could either occur as an isolated condition or as a consequence of chronic plaque psoriasis, with an estimated prevalence of 10.1–76% in all patients with psoriasis.1 A significant aspect of this regional phenotype is its adverse effects on patients’ quality of life (QoL). According to one study, the QoL of approximately 82% of patients with palmoplantar psoriasis was moderately to severely affected.2 This is because patients with palmoplantar psoriasis demonstrate impaired activities of daily living and physical disability.3,4 Moreover, it has been shown that palmoplantar psoriasis is significantly associated with mood disorders, as compared to generalized plaque psoriasis.1 Fortunately, there are numerous therapeutic interventions, such as topical treatments, classical systemic therapy, and biological agents. However, the palmoplantar psoriasis phenotype has been classified as a “difficult to treat psoriasis” due to its frequently reported poor response to therapy.5 Furthermore, evidence-based guidelines addressing the management of this variant are lacking. To the best of our knowledge, there have only been three published randomized controlled trials (Infliximab, Secukinumab, and Ixekizumab) regarding this topic.6–8 Risankizumab, a humanized immunoglobulin G (IgG1) designed to bind the p19 subunit of the IL23 cytokine, is another biological agent that has been approved by the Food and Drug Association (FDA) for chronic plaque psoriasis in 2019.11 In spite of its proven efficacy in chronic plaque psoriasis, there is no dedicated clinical trial assessing its efficacy in restricted palmoplantar psoriasis. Herein, we report the case of a patient with palmoplantar psoriasis to highlight the efficacy of Risankizumab in terms of clinical clearance and rapid onset of action, thereby assessing its therapeutic potential for this phenotype of psoriasis.

Case Report

The patient was a healthy, 25-year-old, Saudi woman, who was diagnosed with palmoplantar psoriasis in 2012. During the disease course, she received multiple, intermittent, super-potent, topical corticosteroids, but did not show improvement. Currently, she is a practicing medical doctor, and her condition prevented her from applying to the general surgery residency program due to functional disability. On physical examination, thick erythematous scaly plaques, with few overlying fissures, on her palms and soles were noted (Figure 1). The patient was also noted to be extremely frustrated by her condition, which has negatively impacted her social and occupational life. Accordingly, we discussed with her the benefits and risks of the available therapeutic interventions, including systemic and biological agents, and suggested the use of an interleukin-23 inhibitor agent (Risankizumab) that was available. She agreed to start Risankizumab and received a total of two doses (baseline and Week 4). By Week 6, the psoriasis on her palms had almost cleared, with only a few remnant scales (Figure 2). The patient was satisfied with the results and was functionally motivated to pursue her occupational objectives.

Figure 1

Well-defined thick erythematous scaling plaques involving both palms of the patient.

Figure 2

Faint erythematous patch with minimal scaling involving both palms of the patient.

Discussion

The severity of palmoplantar psoriasis is well reported in the literature. Despite occurring as an isolated condition, palmoplantar psoriasis can still significantly impact patient QoL.2–4 Thus, its severity should be assessed cautiously, and the surface area of the affected region should not be taken as the sole measure of severity in this regional variant.9 Few randomized clinical trials have been published regarding the efficacy of biological agents in managing palmoplantar psoriasis. An Infliximab pilot study demonstrated failure in reaching the primary endpoint of m-PPPASI75, as compared to that of placebo in a randomized controlled trial, despite its effective superiority to placebo at Week 14 in terms of surface area reduction and m-PPPASI50.7 Similarly, the GESTURE trial revealed that 33.3% and 22.1% of patients on 300-mg and 150-mg Secukinumab, respectively, significantly improved at Week 16, as compared to those with placebo.8 Furthermore, the UNCOVER trials have shown that 80%, 70%, and 50% of patients taking Ixekizumab achieved PPASI50, 75, and 100, respectively, at Week 12.6

In the current era of biologics and molecular treatment, we believe that individualized approaches are needed to address different psoriasis variants. Fortunately, there are many systemic options for psoriasis treatment. Despite these rapid advancements, other issues have risen, such as factors that can affect treatment selection, including insurance systems and health care leaders in the hospital.12 Moreover, with the rapid advancements in biological agents, investigators have begun paying more attention into exploring other outcomes. For example, a previous study reported that TNF-alpha inhibitors may exhibit stronger suppressive properties on inflammatory markers, whereas newer interleukin inhibitors agents may exhibit favorable safety profiles.13 Given this, we hope that this article will contribute to the accumulating evidence that further explores the outcomes for each individual biological agent. We believe that this will help in establishing the unique profile of each agent, such as its efficacy in different phenotypes of psoriasis, with consideration to cost-effectiveness. Such publications may help in providing bases to synthesize evidence-based guidelines that positively affect patient outcomes.

Risankizumab has been reported to be effective in clearing palmoplantar psoriasis after the fourth dose.10 In our case, we documented an almost complete clearance of palmoplantar psoriasis after the second dose at Week 6. This suggests that Risankizumab has a potentially rapid onset of action, making it a highly effective biological agent that could be used in appropriate clinical scenarios where rapid clearance may be needed. However, it should be noted that the main limitation of this article is its nature as a case report. Prospective clinical trials that consider the onset of action and efficacy of Risankizumab are therefore warranted in the future.

Conclusion

Palmoplantar psoriasis should be assessed carefully due to its detrimental effects on patient QoL. Furthermore, a guided protocol is required for managing this particular phenotype. In this era of biological treatment, rapid escalation of management plans may be indicated in the appropriate context. Particularly, Risankizumab can be a potential medication with rapid onset of action against palmoplantar psoriasis, which can lead to significant QoL improvements in the functional aspect of this regional variant.